Investment in skin-whitening agents, boosted by markets in Asian countries, especially those in China, India and Japan, is increasing annually (1)
Alongside doctors experience, real-world data on the use and value of AOMs will begin to accrue as more patients are treated, albeit predominately still in the private market

Food and Drug Administration (2023) Oral semaglutide versus empagliflozin in patients with Type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial, Diabetes Care (2019) Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes, The New England Journal of Medicine (2015) Empagliflozin in heart failure with a preserved ejection fraction, The New England Journal of Medicine e (2021) Empagliflozin in patients with chronic kidney disease, The New England Journal of Medicine (2022) Semaglutide and cardiovascular outcomes in obesity without diabetes, The New England Journal of Medicine (2023) Effects of semaglutide on chronic kidney disease in patients with Type 2 diabetes, The New England Journal of Medicine (2024) Ozempic drug label information, DailyMed (2023) Jardiance drug label information, DailyMed (2023) Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin, and digoxin in healthy subjects, Clinical Pharmacokinetics (2017) Semaglutide injection, Medline Plus (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Retatrutide is not approved for clinical use as of 2026
Biotechnol., vol